Cancer, Signal Transduction and Nanotechnology

Author(s): Poulomi Sengupta, Sudipta Basu, Shiladitya Sengupta

Journal Name: Current Drug Delivery

Volume 8 , Issue 3 , 2011

Become EABM
Become Reviewer

Abstract:

Understanding the mechanisms underlying different cellular signaling pathways implicated in the pathogenesis of cancer are leading to the identification of novel drug targets as well as novel drug candidates. Multiple targeted therapeutics that modulate aberrant molecular pathways have already reached the clinic. However, targeted therapeutics can exert mechanism-driven side effects as a result of the implication of the molecular target in normal physiological functions besides tumorigenesis. We hypothesize that targeted therapeutics can be optimized by merging them with nanotechnology, which offers the potential for preferential targeting to the tumor, resulting in increased intratumoral concentrations of the active agent with reduced distribution to other parts of the body. This review will address some of the emerging concepts that integrate these two disciplines to engineer novel nanovectors that target different signaling pathways.

Keywords: Nanotechnology, drug delivery, signaling pathways, nanoparticles, cancer, RECEPTOR KINASES, Downstream Signaling, ONCOGENIC SIGNALING, EGFR-overexpressing cancer

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 8
ISSUE: 3
Year: 2011
Page: [254 - 260]
Pages: 7
DOI: 10.2174/156720111795256147
Price: $65

Article Metrics

PDF: 17